Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Patrick J Haley

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Exelixis (NASDAQ:EXEL)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Plus de graphiques de la Bourse Exelixis

Exelixis (NASDAQ:EXEL)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025

Plus de graphiques de la Bourse Exelixis

Actualités Exelixis Inc

Form 4 - Statement of changes in beneficial ownership of securities
Mardi 24 Décembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mardi 3 Décembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Vendredi 29 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
Mercredi 27 Novembre 2024 ( il y a 1 mois) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 27 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Mardi 26 Novembre 2024 ( il y a 1 mois) • Business Wire

Form 144 - Report of proposed sale of securities
Vendredi 22 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 20 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 20 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 20 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 20 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 20 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Plus d'articles sur Exelixis Inc

Cie de SaintGobain

Credit Agricole

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales